CABA

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Cabaletta Bio (CABA - Research Report) on November 10 and set a price target of $12.00. The company's shares closed last Friday at $2.38.According to TipRanks, Livshits is a 5-star analyst with an average return of 25.2% and a 41.69% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals, Iovance Biotherapeutics, and Intellia Therapeutics.Currently, the analyst consensus on Cabaletta Bio is a Strong Buy with an average price target of $8.00, implying a 236.13% upside from current levels. In a report released on November 11, H.C.
https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-cabaletta-bio-caba-2?utm_source=advfn.com&utm_medium=referral